StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued to investors on Friday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Performance

Shares of Lipocine stock opened at $3.35 on Friday. Lipocine has a 52 week low of $2.91 and a 52 week high of $11.79. The stock has a 50 day moving average price of $3.95 and a two-hundred day moving average price of $4.54. The stock has a market capitalization of $17.92 million, a PE ratio of -4.41 and a beta of 1.42.

Institutional Investors Weigh In On Lipocine

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC grew its stake in Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 57,464 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,248 shares during the quarter. Geode Capital Management LLC owned approximately 1.07% of Lipocine worth $280,000 at the end of the most recent reporting period. 9.11% of the stock is owned by institutional investors.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.